The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

New prostate cancer drug showing ‘remarkable’ results during clinical trial - The new drug, known as VIR-5500, uses a so-called cloaking device and only activates when it reaches the tumour ...

The Prostate Cancer Foundation (PCF) today announced a $10 million unrestricted gift from an anonymous donor to launch a ...

Prostate cancer screening compares favorably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding unnecessary harms, says new research. The findings are ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

Winship Cancer Institute of Emory University, a nonprofit medical research center based out of Atlanta, has launched a new mobile prostate cancer screening program. Backed by the Arthur M. Blank ...

Urologists, radiologists and pathologists from Europe and the US agreed an “expert consensus statement” on prostate cancer treatment and diagnosis ...

March 15, 2026 expert reaction to conference abstract comparing prostate cancer and breast cancer screening programmes, being presented at the European Association of Urology Cong ...

Nearly 300 abstracts on prostate cancer research from around the world will be presented at the European Association of Urology Congress (EAU26), taking place in London from 13–16 March 2026.

Prostate cancer screening compares favourably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding ...

Florida Cancer Specialists & Research Institute, LLC (FCS) advances genitourinary cancer treatment through participation at the global ASCO® 2026 Genitourinary (GU) Cancers Symposium meeting this ...